Nov 13, 2024 / 01:00PM GMT
Editor
Portions of this transcript marked (technical difficulty) indicate audio problems. The missing text will be supplied if a replay becomes available.
Paula Ragan - X4 Pharmaceuticals Inc - President, Chief Executive Officer, Secretary, Director
(technical difficulty) As well as healthy donors for a comparison. And we'll briefly review the updated safety data from the study as well.
We'll then conclude and open it up for your questions when we will be joined by our Chief Commercial Officer, Mark Fry, our Chief Financial Officer, Adam Mustapha, our Chief Operating Officer, Dr Mary, via our Chief Scientific Officer, Dr Art Taveras and our head of corporate and patient affairs, Jose Juve.
So let's quickly run through the operational update as we know you're all eager to hear about the CN phase two study results and analysis.
As you know, we received us FDA approval in late April for our first product Maverick for branded Zol rmdy for the whim syndrome, a rare primary immunodeficiency disease.
As with ultra rare disease launches.
Q3 2024 X4 Pharmaceuticals Inc Earnings Call Transcript
Nov 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers